🇺🇸 FDA
Patent

US 12064473

Cancer vaccines targeting Survivin and uses thereof

granted A61KA61K2039/53A61K2039/55527

Quick answer

US patent 12064473 (Cancer vaccines targeting Survivin and uses thereof) held by Inovio Pharmaceuticals, Inc. expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inovio Pharmaceuticals, Inc.
Grant date
Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K2039/53, A61K2039/55527, A61K2039/575, A61K39/00115